[Form 4] The Gabelli Healthcare & Wellness Trust Insider Trading Activity

Rhea-AI Filing Summary

Saba Capital Management, L.P., a 10% owner of Gabelli Healthcare & WellnessRx Trust (GRX), filed a Form 4 dated 14-Jul-2025 reporting two open-market purchases.

• 07-Jul-2025: 3,952 common shares bought at $9.48
• 11-Jul-2025: 6,894 common shares bought at $9.37

The combined 10,846-share acquisition cost roughly $102 k and lifts Saba’s indirect ownership to 1,987,721 shares. No derivative securities were reported. The filing was signed by Zachary Gindes for Saba and by Boaz Weinstein, confirming the transactions. The added position represents an incremental increase of approximately 0.55 % to Saba’s existing stake.

Positive

• 10,846 new shares acquired by a 10% owner indicates ongoing insider confidence.

Negative

• None.

Insights

Securities Analyst

TL;DR Saba's 10,846-share purchase is a mildly positive but immaterial incremental increase in its GRX position.

The insider filing shows continued accumulation by the fund but the size—about US$102 k—does not materially change ownership (now 1.99 m shares). No derivatives or sales were disclosed, suggesting no hedging or profit-taking. From a valuation perspective, insider buying is directionally positive, yet the small percentage change limits its financial significance. Overall impact: neutral to slightly positive.

Portfolio Manager

TL;DR Incremental buy signals confidence, but scale too small to drive GRX price action.

Saba, led by activist investor Boaz Weinstein, added just 0.55 % to an already large position. The absence of sales underscores a bullish stance, yet without a sizable percentage swing or strategic disclosure, the market should not re-rate GRX materially on this data alone. I view the filing as not impactful for portfolio weighting decisions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saba Capital Management, L.P.

(Last) (First) (Middle)

405 LEXINGTON AVENUE

58TH FLOOR

(Street)

NEW YORK NY 10174

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Gabelli Healthcare & WellnessRx Trust [ GRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2025		P		3,952	A	$9.48	1,980,827	I	-
Common Stock	07/11/2025		P		6,894	A	$9.37	1,987,721	I	-

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Saba Capital Management, L.P.

(Last) (First) (Middle)

405 LEXINGTON AVENUE

58TH FLOOR

(Street)

NEW YORK NY 10174

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Weinstein Boaz

(Last) (First) (Middle)

405 LEXINGTON AVENUE

58TH FLOOR

(Street)

NEW YORK NY 10174

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

	Saba Capital Management, L.P. By: Zachary Gindes	07/14/2025
	Boaz Weinstein	07/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many GRX shares did Saba Capital purchase?

10,846 common shares were bought across two transactions.

At what prices were the GRX shares bought?

Shares were purchased at $9.48 on 07/10/2025 and $9.37 on 07/11/2025.

What is Saba Capital’s total GRX ownership after the purchases?

The fund now indirectly holds 1,987,721 common shares.

Were any derivative securities involved in these transactions?

No, the Form 4 reported no derivative transactions.

What percentage increase does the purchase represent?

Approximately 0.55 % increase in Saba’s existing GRX position.